Business Wire

Esmark’s Second Donation of $25,000 to Aid Ukrainian Refugees Fleeing to Slovakia Brings Contribution Total to $50,000; Company Rallies Nearly $12,000 in Additional Support

11.4.2022 14:45:00 EEST | Business Wire | Press release

Share

Esmark Inc. today announced that Chairman & CEO James P. Bouchard and long-time friend Martina Roda have made a second donation of $25,000 USD to aid and support Ukrainians seeking refuge in Košice, Slovakia. This is the Company’s second donation to City of Košice, a city led by Mayor Ing. Jaroslav Polaček, to aid Ukrainians fleeing to Slovakia.

As of April 5, more than 302,700 Ukrainian refugees have entered Slovakia, according to a verified operational data portal.

The Company’s donations to the relief efforts now total $50,000 USD. In March, Esmark announced an initial donation of $25,000 USD and—in an effort to mobilize others to help—offered to match donations up to an additional $25,000 USD. To date, Esmark was directly notified of nearly $12,000 USD in donations made by Americans to support Ukrainian refugees.

Bouchard is a former U.S. Steel executive vice president and statutory representative of the Slovak Republic, transforming East Slovakian Ironworks, Košice–now known as U.S. Steel Košice–in Slovakia after U.S. Steel acquired it. Bouchard and Roda’s donations totaling $50,000 were made on behalf of the former U.S. Steel American and Slovak Commercial teams.

“While we are proud and grateful for the nearly $12,000 in donations made by Esmark friends, we couldn’t wait another moment to provide additional monetary support to the city Košice,” said Bouchard. “We are working directly with the Mayor’s office which ensures our funds are delivered immediately, enabling them to take swift action and help these refugees with humanitarian support.”

The funds from the initial donation were used to:

- Rent an agency as organizational and technical support in the center for Ukrainian refugees;

- Provide provisions and organization of Slovakian volunteers; and

- Coordinate temporary accommodation and provide provisions to Ukrainian refugees.

“The initial $25,000 from Jim and Martina enabled us to mobilize and organize more quickly,” said Košice City Mayor Ing. Jaroslav Polaček. “We are very grateful for the additional $25,000 of support, which we will focus mainly on providing transportation, accommodation and food especially for families with young children. “

“We cannot standby as we hear the first-hand accounts from our friends on the ground in Slovakia and continue to watch these events unfold on the news,” said Roda. ”We commend the Mayor, volunteers and all people of Košice who are providing much needed humanitarian support to their Ukrainian neighbors.”

Esmark and Bouchard have a history of and commitment to helping others in need. Over the last 15 years, more than $10 million has been donated to humanitarian relief and children’s charities.

About Esmark, Inc.

Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye